张莉萍 田庭雅 (武汉市普爱医院 武汉 430030)
摘 要 目的：探讨普伐他汀和非诺贝特联合应用治疗混合性高脂血症的疗效及安全性。方法：102例混合性高脂血症患者，随机分为普伐他汀组(10 mg/d，n=51)和联合治疗组(普伐他汀10 mg/d+非诺贝特200 mg/d,n=51),共治疗6个月。观察治疗前后主要血脂参数的变化、总有效率、与治疗安全性有关的指标以及不良反应。结果：联合治疗组血脂参数的变化率最显著,血清总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和甘油三酯（TG）分别下降30%、36%和55%，而血清高密度脂蛋白胆固醇（HDL-C）升高24%，联合治疗组TG.和HDL-C的总有效率明显高于普伐他汀组(P<0.01)。结论：普伐他汀与非诺贝特联合治疗混合性高脂血症患者能更全面调节血脂异常，疗效优于单用普伐他汀治疗。
关键词 混合性高脂血症；调脂药；药物疗效; 联合
中图分类号：R972+.6
文献标识码：A
文章编号：1008-049X(2007)07-0687-03
Efficacy of Combination Therapy with Pravastatin and Fenofibrate for Mixed Hyperlipidemia
Zhang Liping，Tian Tingya(Department of Cardiology ，Puai Hospital of Wuhan，Wuhan 430030，China)
ABSTRACT Objective: To evaluate the efficacy and safety of combination therapy with pravastatin and fenofibrate in patients with mixed hyperlipidemia.Method: A total of 102 patients with mixed hyperlipidemia. were randomly assigned to receive pravastatin 10 mg(n=51) or a combination of pravastatin 10 mg fenofibrate 200 mg(n=51) for 6 months.Lipid profiles,physical and laboratory investigations for efficacy, safety and adverse effecs were assessed.Result:combination treatment were more effective in normalizing lipid profile than any monotherapy.Serum TC,LDL-C,and Tg were reduced by 30%,36%,and 55%respectively,whilst HDL-C was significantly increased by 24%.A total effective rate of combination treatment in TG and HDL-C was superior to pravastatin.
Conclusion: combination therapy with fenofibrate and pravastatin is more effective than monotherapy in patients with mixed hyperlipidemia.
KEY WORDS Mixed hyperlipidemia;Antilipemic agents;combination;Drug therapy
参 考 文 献
1 Sow V,Aronson MD,Hornbake ER,et al.Lipid control in the management of type 2 diabetes mellitus:a clinical practice guideline from the American College of Physicians［J］.Ann Intern Med,2004,140:644-649
2 American diabetes association,Dyslipiddemia management in adults with diabetes［J］.Diabetes Care,2004,27(Suppl):S68-S71
3 血脂异常防治对策专题组. 血脂异常防治建议［J］.中华心血管病杂志,1997,3:169-175
4 Pastemak RC, Sminth SC Jr,BaireyMerz CN,et al.ACC/AHA/NHLBI Clincal Advisory on the Use and Safety OF Statins［J］. Circulation,2002,106:102401028
5 Sacks FM. The role of HDL-C in the prevention and treatment of coronary heart disease:expert group recommendation ［J］. AMJ Cardiol,2002,90:139-143
6 叶平.心血管病高危患者强化降脂的新证据,从ATPⅢ指南修订:看降脂治疗的新动向［J］.心肺血管病论坛,2005,5:20-23
7 Allen J,Lance E,Hyun J, et al.Arterial Biology for the Inveatigation of the Treatment Effects of Reducing Cholesterol (ARBITER)2: A Double-Blind, Placebo-Controlled Study of ExtendedRelease Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins［J］. Circulation,2004,110:3512-3517 资料来自:中国药师-专业站 |